Abstract
Complex and variable morphological phenotypes pose a major challenge to the histopathological classification of neuroepithelial tumors. This applies in particular for low-grade gliomas and glio-neuronal tumors. Recently, we and others have identified microtubule-associated protein-2 (MAP2) as an immunohistochemical marker expressed in the majority of glial tumors. Characteristic cell morphologies can be recognized by MAP2 immunoreactivity in different glioma entities, i.e., process sparse oligodendroglial versus densely ramified astrocytic elements. Here, we describe MAP2-immunoreactivity patterns in a large series of various neuroepithelial tumors and related neoplasms (n=960). Immunohistochemical analysis led to the following conclusions: (1) specific pattern of MAP2-positive tumor cells can be identified in 95% of glial neoplasms; (2) ependymal tumors do not express MAP2 in their rosette-forming cell component; (3) tumors of the pineal gland as well as malignant embryonic tumors are also characterized by abundant MAP2 immunoreactivity; (4) virtually no MAP2 expression can be observed in the neoplastic glial component of glio-neuronal tumors, i.e. gangliogliomas; (5) malignant glial tumor variants (WHO grade III or IV) exhibit different and less specific MAP2 staining patterns compared to their benign counterparts (WHO grade I or II); (6) with the exception of melanomas and small cell lung cancers, MAP2 expression is very rare in metastatic and non-neuroepithelial tumors; (7) glial MAP2 expression was not detected in 56 non-neoplastic lesions. These data point towards MAP2 as valuable diagnostic tool for pattern recognition and differential diagnosis of low-grade neuroepithelial tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barker FG II, Davis RL, Chang SM, et al (1996) Necrosis as a prognostic factor in glioblastoma multiforme. Cancer 77:1161–1166
Biegel JA, Zhou JY, Rorke LB, et al (1999) Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59:74–79
Blümcke I, Wiestler OD (2002) Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 61:575–584
Blümcke I, Becker AJ, Normann S, et al (2001) Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells. J Neuropathol Exp Neurol 60:984–993
Blümcke I, Luyken C, Urbach H, et al (2004) An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis. Acta Neuropathol 107:381–388
Burger PC, Green SB (1987) Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59:1617–1625
Cairncross JG, Ueki K, Zlatescu MC, et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479
Cosenza MA, Zhao ML, Shankar SL, et al (2002) Up-regulation of MAP2e-expressing oligodendrocytes in the white matter of patients with HIV-1 encephalitis. Neuropathol Appl Neurobiol 28:480–488
Dehghani F, Maronde E, Schachenmayr W, et al (2000) Neurofilament H immunoreaction in oligodendrogliomas as demonstrated by a new polyclonal antibody. Acta Neuropathol (Berl) 100:122–130
Huber G, Matus A (1984) Differences in the cellular distributions of two microtubule-associated proteins, MAP1 and MAP2, in rat brain. J Neurosci 4:151–160
Kirchner T (2000) [The pathologist as a discover of patterns. Perspectives in disease morphology]. Pathologe 21:281–284
Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. World Health Organization classification of tumours. Lyon, IARC
Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159:779–786
Ng HK, Ko HCW, Tse CCH (1994) Immunohistochemical and ultrastructural studies of oligodendrogliomas revealed features of neuronal differentiation. Int J Surg Pathol 2:47–56
Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126
Riederer B, Matus A (1985) Differential expression of distinct microtubule-associated proteins during brain development. Proc Natl Acad Sci USA 82:6006–6009
Riederer BM, Draberova E, Viklicky V, et al (1995) Changes of MAP2 phosphorylation during brain development. J Histochem Cytochem 43:1269–1284
Schramm J, Luyken C, Urbach H, et al (2004) Evidence for a clinically distinct new subtype of grade II astrocytomas in patients with long-term epilepsy. Neurosurgery (in press)
Shafit-Zagardo B, Kress Y, Zhao ML, et al (1999) A novel microtubule-associated protein-2 expressed in oligodendrocytes in multiple sclerosis lesions. J Neurochem 73:2531–2537
Shafit-Zagardo B, Davies P, Rockwood J, et al (2000) Novel microtubule-associated protein-2 isoform is expressed early in human oligodendrocyte maturation. Glia 29:233–245
Suzuki SO, Kitai R, Llena J, et al (2002) MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration. J Neuropathol Exp Neurol 61:403–412
Acknowledgements
The study was supported by grants of the Deutsche Forschungsgemeinschaft (SFB 400). B.M.R. is supported by grant no. 3100-067201.01 of the Swiss National Science Foundation for Scientific Research. We kindly thank G. Reifenberger (University of Düsseldorf) for his support. C. Ullmann (University of Bonn) is acknowledged for her expert technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blümcke, I., Müller, S., Buslei, R. et al. Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors. Acta Neuropathol 108, 89–96 (2004). https://doi.org/10.1007/s00401-004-0873-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-004-0873-8